Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tarlatamab + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Tarlatamab + carboplatin + etoposide is an investigational combination regimen being evaluated for the treatment of relapsed extensive-stage small cell lung cancer (ES-SCLC). The combination consists of tarlatamab, a half-life extended bispecific T-cell engager (BiTE) that targets delta-like ligand 3 (DLL3) on tumor cells and CD3 on T cells, alongside standard platinum-based chemotherapy (carboplatin and etoposide). Tarlatamab redirects cytotoxic T cells to DLL3-expressing cancer cells, which are prevalent in SCLC. Carboplatin and etoposide are cytotoxic agents that induce DNA damage and inhibit topoisomerase II, respectively. This specific triplet is being investigated in the REPLAT trial as a rechallenge strategy for patients who have previously progressed on tarlatamab monotherapy, based on the hypothesis that chemotherapy may synergistically enhance T-cell infiltration and modify the tumor microenvironment to overcome resistance.
- Brand names
- Imdelltra + carboplatin + etoposide
- Other names
- REPLAT regimen
02
Targets
CD3 (T-cell surface glycoprotein CD3)TOP2A (DNA topoisomerase II)DLL3 (Delta-like ligand 3)DNA
Beyond the preview
Go deeper on tarlatamab + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tarlatamab + carboplatin + etoposide.